Some of the losses seen by insiders who purchased US$398.0k worth of Rezolute, Inc. (NASDAQ:RZLT) shares over the past year were recovered after the stock increased by 11% over the past week. However, the purchase is proving to be an expensive wager as insiders are yet to get ahead of their losses which currently stand at US$77k since the time of purchase.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
The Last 12 Months Of Insider Transactions At Rezolute
Notably, that recent purchase by Daron Evans is the biggest insider purchase of Rezolute shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$3.02. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Rezolute share holders is that insiders were buying at near the current price.
In the last twelve months Rezolute insiders were buying shares, but not selling. They paid about US$3.75 on average. I'd consider this a positive as it suggests insiders see value at around the current price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for Rezolute
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insiders At Rezolute Have Bought Stock Recently
Over the last quarter, Rezolute insiders have spent a meaningful amount on shares. Overall, three insiders shelled out US$159k for shares in the company -- and none sold. This could be interpreted as suggesting a positive outlook.
Insider Ownership
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data suggests Rezolute insiders own 0.8% of the company, worth about US$1.5m. We consider this fairly low insider ownership.
What Might The Insider Transactions At Rezolute Tell Us?
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Rezolute stock. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Rezolute has 3 warning signs (and 2 which are a bit unpleasant) we think you should know about.
Of course Rezolute may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:RZLT
Rezolute
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Flawless balance sheet and good value.
Similar Companies
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Recently Updated Narratives
Hims & Hers Health aims for three dimensional revenue expansion
Endeavour Group's Future PE Expected to Climb to 15.51%
A Quality Compounder Marked Down on Overblown Fears
Popular Narratives

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
